EQ-5D-5L utilities per health states in Spanish population with knee or hip osteoarthritis

García-Pérez, Lidia; Ramos-García, Vanesa; Serrano-Aguilar, Pedro; Pais-Brito, José Luis; Aciego de Mendoza, María; Martín-Fernández, Jesús; García-Maroto, Roberto; Arenaza, Juan Carlos; Bilbao, Amaia

doi:10.1186/s12955-019-1230-x

Health and Quality of Life Outcomes

Table 5 Utility weights (EQ-5D-5 L Index) per subgroup in patients with hip osteoarthritis

From: EQ-5D-5L utilities per health states in Spanish population with knee or hip osteoarthritis

Subgroup		N	Mean	SD	P-value
Age groups (years)	< 45	13	0.591	0.357	0.259
	45–54.99	37	0.506	0.291
	55–64.99	83	0.465	0.291
	65–74.99	101	0.507	0.298
	75–84.99	103	0.562	0.299
	≥85	20	0.584	0.380
Gender	Women	188	0.512	0.305	0.606
Gender	Men	169	0.529	0.304	0.606
Region	Basque Country^a	154	0.473	0.313	0.036
	Madrid^b	124	0.553	0.288
	Canary Islands^c	79	0.562	0.301
BMI categories	Underweight	2	0.339	0.572	0.372
	Normal	87	0.552	0.305
	Overweight	154	0.530	0.288
	Obesity	102	0.473	0.324
	Morbid obesity	5	0.541	0.241
Joint with osteoarthritis	Right hip	135	0.481	0.320	0.059
	Left hip	121	0.571	0.285
	Both hip	101	0.511	0.297
Time since osteoarthritis diagnosis (years)	<1	118	0.541	0.279	0.240
	1 to <5	152	0.492	0.309
	5 to < 10	63	0.520	0.347
	10 to < 15	14	0.675	0.204
	≥15	8	0.523	0.288
Contralateral hip	Without prosthesis in the other hip	293	0.510	0.303	0.182
Contralateral hip	With prosthesis in the other hip	62	0.567	0.302	0.182
Other joints	Knee osteoarthritis	115	0.522	0.322	0.303
	No knee osteoarthritis	241	0.521	0.295	0.303
	Osteoarthritis in other joints	214	0.537	0.301	0.801
	No osteoarthritis in other joints	142	0.499	0.306	0.801
Number of comorbidities (Charlson Index)	No comorbidity^a	206	0.561	0.284	0.033
	1 comorbidity^b	71	0.465	0.323
	2 comorbidities^c	46	0.495	0.334
	3 comorbidities^d	18	0.386	0.370
	≥4 comorbidities^e	16	0.460	0.210
WOMAC	Pain score 0 to <25^a	54	0.818^bcd	0.146	< 0.0001
	Pain score 25 to <50^b	143	0.643^acd	0.175
	Pain score 50 to <75^c	110	0.414^abd	0.243
	Pain score 75 to 100^d	49	0.074^abc	0.250
	Stiffness score 0 to <25^a	42	0.795^bcd	0.181	< 0.0001
	Stiffness score 25 to <50^b	107	0.656^acd	0.220
	Stiffness score 50 to <75^c	118	0.509^abd	0.241
	Stiffness score 75 to 100^d	89	0.243^abc	0.294
	Physical function score 0 to <25^a	48	0.878^bcd	0.098	< 0.0001
	Physical function score 25 to <50^b	115	0.672^acd	0.144
	Physical function score 50 to <75^c	125	0.464^abd	0.225
	Physical function score 75 to 100^d	69	0.120^abc	0.229
	WOMAC Score 0 to <25^a	47	0.864^bcd	0.122	< 0.0001
	WOMAC Score 25 to <50^b	124	0.673^acd	0.145
	WOMAC Score 50 to <75^c	120	0.429^abd	0.232
	WOMAC Score 75 to 100^d	56	0.081^abc	0.222
Oxford Hip Score (OHS)	Severe (0–19)^a	149	0.269^bcd	0.264	< 0.0001
	Moderate to severe (20–29)^b	116	0.611^acd	0.146
	Mild to moderate (30–39)^c	61	0.783^abd	0.101
	Satisfactory joint function (40–48)^d	29	0.903^abc	0.102
Non-surgery treatments	No pharmacologic treatment	69	0.544	0.312	0.491
	Any pharmacologic treatment	287	0.516	0.301	0.491
	Symptomatic slow acting drugs for osteoarthritis (SYSADOA)	34	0.574	0.320	0.331*
	Non-opioid pain medication	197	0.503	0.309	0.435*
	Nonsteroidal anti-inflammatory drugs (NSAID)	128	0.533	0.304	0.613*
	Opiate derivatives	97	0.498	0.304	0.474*
	Opioid pain medication	13	0.435	0.378	0.434*
	Rehabilitation / Physiotherapy	10	0.598	0.227	0.305*
Hip replacement	Waiting for prosthesis	97	0.379	0.313	< 0.0001**
	Prosthesis in the last 6 months	65	0.730	0.208	< 0.0001**
	Complication after prosthesis	5	0.556	0.432	–

BMI Body mass index; SD Standard deviation; WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
P-values represents the significance of differences between groups by means of ANOVA except for (*) P-value comparing with the whole sample’s utility value (0.520) (one sample t-test), and (**) P-value comparing sample before and after (6 months) the prosthesis (paired sample t-test)
Superscript letters indicate differences among the subgroups according to Bonferroni (region and number of comorbidities) or Tamhane’s T2 (WOMAC, OHS) post hoc tests for multiple comparisons at P-value< 0.01

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com